Role of anti-PF4/heparin antibodies in recurrent thrombotic events after acute coronary syndromes.
We postulated that patients with recent acute coronary syndromes and antibodies to the platelet factor 4/heparin complex would have an increased risk of myocardial infarction (MI), even in the absence of thrombocytopenia. We analyzed sera from patients enrolled in the placebo/unfractionated heparin arm of the GUSTO IV-ACS trial who had a high likelihood of prior heparin exposure. We selected 109 patients without thrombocytopenia with the 30-day primary endpoint (death, MI, or revascularization) and 109 age-, gender-, and race-matched controls who did not achieve the primary endpoint. Twenty-three of 218 patients (10.6%) had anti-PF4/heparin antibodies. Patients with anti-PF4/heparin were more likely to have death or MI (30.4% vs. 11.3%, p = 0.011) or MI (21.7% vs. 6.2%, p = 0.008) than patients who were negative for the antibody. Antibody-positive patients had higher levels of sVCAM-1 (892 +/- 263 microg/L vs. 780 +/- 228 microg/L; p = 0.04) and sICAM-1 (246 +/- 50 microg/L vs. 222 +/- 71 microg/L; p = 0.02) than antibody-negative patients. In a multiple logistic regression model that included inflammatory markers and clinical risk factors, antibodies to PF4/heparin were a strong predictor of 30-day MI (odds ratio, 9.0; 95% confidence intervals, 2.1 to 38.6; p < 0.01), with IL-6 being the only other predictor (odds ratio, 1.1; 95% confidence intervals, 1.0 to 1.2; p = 0.03). Antibodies to the platelet factor 4/heparin complex are a novel, independent predictor of MI at 30 days in patients presenting with acute coronary ischemic syndromes. Antibodies to PF4/heparin are a stronger predictor of MI than clinical characteristics or inflammation markers.
Mascelli
Mary Ann
MA
Centocor, Malvern, Pennsylvania, USA.
Deliargyris
Efthymios N
EN
Damaraju
Lakshmi V
LV
Barnathan
Elliot S
ES
Sane
David C
DC
D000077284:Abciximab; D000208:Acute Disease; D000906:Antibodies / Q000737:chemistry*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D001792:Blood Platelets / Q000276:immunology; D002986:Clinical Trials as Topic; D005260:Female; D006331:Heart Diseases / Q000150:complications / Q000473:pathology*; D006493:Heparin / Q000737:chemistry / Q000276:immunology*; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use; D007249:Inflammation; D018799:Intercellular Adhesion Molecule-1 / Q000097:blood; D008297:Male; D009203:Myocardial Infarction; D016017:Odds Ratio; D010919:Placebos; D010978:Platelet Factor 4 / Q000276:immunology*; D012008:Recurrence; D013927:Thrombosis / Q000209:etiology*; D013997:Time Factors; D019010:Vascular Cell Adhesion Molecule-1 / Q000097:blood
D000906:Antibodies; D000911:Antibodies, Monoclonal; D000925:Anticoagulants; D007140:Immunoglobulin Fab Fragments; D010919:Placebos; D019010:Vascular Cell Adhesion Molecule-1; D018799:Intercellular Adhesion Molecule-1; D010978:Platelet Factor 4; D006493:Heparin; D000077284:Abciximab